Faculty introduction, disclosures

Introduction content: cursory refresher and review of PD Epidemiology: statistics by severity Clinical features, presentation (motor symptoms), pathophysiology, risk factors (e.g., Gaucher’s disease, differential diagnosis and disease progression Patient case(s)

Treatment of PD Clinical trial findings and evidence update Present pharmacotherapy Treatment-refractory disease and complications Management of motor fluctuations and dyskinesia Management of related casualties of disease: psychosis, depression, mood disturbances, dementia, sleep disturbance, sensory derangement, impaired cognition, and autonomic defects Other clinical pearls A distinction between disease progression and adherence to therapy Emerging and future therapies Barriers to care: optimizing patients’ adherence to their therapy and minimizing adverse effects Patient case(s)

By the end of the session the participant will be able to:

• Describe the epidemiology of PD and outline current and evolving diagnostic criteria
• Describe the challenges associated with the diagnosis of PD
• Identify the treatment modalities currently available for management of PD and its complications and apply them to patient cases using evidence-based medicine
• List emerging pharmacologic therapies for the treatment of PD
• Describe the impact of medication adherence on patient outcomes and formulate strategies to improve adherence in patients with PD

ACCME Activity #201226438

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosures:

Dr. Natalie Diaz, MD, Associate Professor in Neurology, David Geffen School of Medicine at UCLA, has received research support from Pfizer, Civitas, Chelsea, Adamas, SK Life.

 

 

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.

 

Commercial Support Disclosure: This program is supported by an educational grant from Acorda

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version